Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
NCT06588868 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2025-12-02
Summary
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
Conditions
- Cutaneous T Cell Lymphoma
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Cutaneous T-Cell Lymphoma/Sezary Syndrome
Sponsors & Collaborators
- collaborator INDUSTRY
-
Fondazione Italiana Linfomi - ETS
lead OTHER
Principal Investigators
-
Pietro Quaglino, MD · SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-27
- Primary Completion
- 2026-07-31
- Completion
- 2026-07-31
Countries
- Italy
Study Locations
More Related Trials
-
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
NCT02788916 ·Status: COMPLETED
-
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
NCT06588205 ·Status: RECRUITING
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
NCT06835530 ·Status: RECRUITING ·Phase: PHASE2
-
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
NCT00051012 ·Status: COMPLETED ·Phase: PHASE4
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
NCT05249959 ·Status: RECRUITING ·Phase: PHASE2
-
Diagnostic Classifier for Cutaneous T-cell Lymphomas
NCT04491825 ·Status: UNKNOWN
-
A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice
NCT06008691 ·Status: RECRUITING
-
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
NCT06716658 ·Status: RECRUITING ·Phase: PHASE2
-
Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis
NCT02520908 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
NCT07213882 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
NCT02323659 ·Status: TERMINATED ·Phase: PHASE4
-
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
NCT00050999 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00425555 ·Status: COMPLETED ·Phase: PHASE2
-
Study on Plasmablastic Lymphoma Patients
NCT06781359 ·Status: RECRUITING
-
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma
NCT04183569 ·Status: UNKNOWN
-
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
NCT06289959 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
NCT04998669 ·Status: RECRUITING ·Phase: PHASE2
-
A Retrospective Study on Extranodal DLBCL
NCT06549361 ·Status: COMPLETED
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689 ·Status: RECRUITING ·Phase: PHASE1
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN